<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002443</url>
  </required_header>
  <id_info>
    <org_study_id>246B</org_study_id>
    <nct_id>NCT00002443</nct_id>
  </id_info>
  <brief_title>The Safety and Effectiveness of MK-639 and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs</brief_title>
  <official_title>Twelve-Month Study in HIV-1 Seropositive Retroviral-Naive Patients to Compare the Safety and Efficacy of MK-639 and Zidovudine (AZT) Administered Concomitantly to MK-639 Alone and Zidovudine (AZT) Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NIH AIDS Clinical Trials Information Service</source>
  <brief_summary>
    <textblock>
      To compare the effects on CD4 counts and safety of MK-639 (indinavir, IDV) and AZT&#xD;
      administered concomitantly to MK-639 alone and AZT alone in HIV-1 seropositive patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients are randomized to 1 of 3 groups for 12 months of treatment. Group 1 receives MK-639&#xD;
      plus AZT. Group 2 receives MK-639 alone. Group 3 receives AZT alone. Safety and tolerability&#xD;
      are assessed by the incidence of clinical and laboratory adverse experiences. Blood and urine&#xD;
      samples are collected for safety assessment and to determine CD4 cell counts and serum viral&#xD;
      RNA levels. If therapy with MK-639 alone or with AZT is found to be generally safe and&#xD;
      clinically efficacious, patients who have completed the study will have the opportunity to&#xD;
      continue in an extension study protocol on a treatment regimen including MK-639.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date>January 1996</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>780</enrollment>
  <condition>HIV Infections</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Indinavir sulfate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zidovudine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
        Patients must have:&#xD;
&#xD;
          -  HIV seropositivity.&#xD;
&#xD;
          -  Average CD4 count between 50 and 500 cells/mm3 based on 2 separate pre-study&#xD;
             determinations at least 1 week apart.&#xD;
&#xD;
        Note:&#xD;
&#xD;
          -  Patients with known hemophilia may be enrolled at the discretion of the investigator.&#xD;
&#xD;
        Prior Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
          -  Any protease inhibitor.&#xD;
&#xD;
          -  Significant prior use (greater than 2 weeks) of nucleoside analogues.&#xD;
&#xD;
          -  Chronic therapy for an active opportunistic infection. (Allowed:&#xD;
&#xD;
          -  Prophylaxis with aerosolized pentamidine, trimethoprim/sulfamethoxazole, dapsone,&#xD;
             topical antifungals, and isoniazid).&#xD;
&#xD;
          -  Investigational agents or immunomodulators within 30 days prior to study entry.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Co-existing Condition:&#xD;
&#xD;
        Patients with the following symptoms or conditions are excluded:&#xD;
&#xD;
          -  Acute hepatitis.&#xD;
&#xD;
          -  Lymphoma.&#xD;
&#xD;
          -  Visceral Kaposi's sarcoma.&#xD;
&#xD;
          -  Invasive cervical cancer.&#xD;
&#xD;
          -  Active infection.&#xD;
&#xD;
        Concurrent Medication:&#xD;
&#xD;
        Excluded:&#xD;
&#xD;
        Anticipated immunosuppressive therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 1996</verification_date>
  <study_first_submitted>November 2, 1999</study_first_submitted>
  <study_first_submitted_qc>August 30, 2001</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 31, 2001</study_first_posted>
  <last_update_submitted>June 23, 2005</last_update_submitted>
  <last_update_submitted_qc>June 23, 2005</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2005</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Indinavir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

